Five-year results are in for pembrolizumab
The PD-1 antibody 'confers sustained disease control over a long period of time' in advanced melanoma
Confirmation that pembrolizumab (Keytruda) is a more effective medication for advanced melanoma than ipilimumab (Yervoy) comes from a five-year follow-up of a clinical trial.
The original study (KEYNOTE-006) randomised patients to one of two regimens of the programmed cell-death-1 (PD-1) antibody, pembrolizumab or to ipilimumab (a cytotoxic T-lymphocyte-associated antigen-4 antibody).
